Additional file 1: of The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells

Sheet 1: Summery of acquired genomic alterations being selected for during docetaxel exposure in the MCF-7 sub-lines. Sheet 2: Details on the acquired genomic alterations being selected for during docetaxel exposure in the MCF-7 sub-lines. Positions are annotated with Ensembl VEP (version 2.8). The stage (sub-line) in which the alteration was acquired is given along with assigned variant class. Sheet 3: Same as sheet 2, but showing only Class A variation. Sheet 4: Same as sheet 3, but showing only the ‘most severe’ variant per gene. Sheet 5: Summery of acquired genomic alterations being selected for during docetaxel exposure in the MDA-MB-231 sub-lines. Sheet 6: Details on the acquired genomic alterations being selected for during docetaxel exposure in the MDA-MB-231 sub-lines. Positions are annotated with Ensembl VEP (version 2.8). The stage (sub-line) in which the alteration was acquired is given along with assigned variant class. Sheet 7: Same as sheet 6, but showing only Class A variation. Sheet 8: Same as sheet 7, but showing only the ‘most severe’ variant per gene. (XLSX 1113 kb)

工作表1：多西他赛（docetaxel）处理筛选获得的MCF-7亚系中获得性基因组变异汇总。工作表2：多西他赛处理筛选获得的MCF-7亚系中获得性基因组变异详情。变异位点采用Ensembl变异效应预测器（Ensembl VEP，版本2.8）进行注释，同时标注变异获得时的细胞亚系阶段及所分配的变异类型。工作表3：与工作表2内容一致，但仅展示A型变异。工作表4：与工作表3内容一致，但仅展示每个基因的「最严重」变异。工作表5：多西他赛处理筛选获得的MDA-MB-231亚系中获得性基因组变异汇总。工作表6：多西他赛处理筛选获得的MDA-MB-231亚系中获得性基因组变异详情。变异位点采用Ensembl变异效应预测器（Ensembl VEP，版本2.8）进行注释，同时标注变异获得时的细胞亚系阶段及所分配的变异类型。工作表7：与工作表6内容一致，但仅展示A型变异。工作表8：与工作表7内容一致，但仅展示每个基因的「最严重」变异。（XLSX格式，文件大小1113 KB）